Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DURVALUMAB for K-ras gene mutation: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 5 adverse event reports in the FDA FAERS database where DURVALUMAB was used for K-ras gene mutation.

Most Reported Side Effects for DURVALUMAB

Side Effect Reports % Deaths Hosp.
Death 2,817 16.4% 2,816 98
Malignant neoplasm progression 1,330 7.8% 343 166
Pneumonitis 827 4.8% 221 333
Radiation pneumonitis 786 4.6% 112 343
Pyrexia 573 3.3% 79 372
Diarrhoea 530 3.1% 99 267
Pneumonia 453 2.6% 169 300
Dyspnoea 444 2.6% 113 215
Interstitial lung disease 430 2.5% 144 220
Off label use 395 2.3% 70 102
Fatigue 367 2.1% 57 102
Rash 359 2.1% 43 94
Neutrophil count decreased 343 2.0% 49 76
Asthenia 326 1.9% 104 121
Colitis 319 1.9% 73 164

Other Indications for DURVALUMAB

Non-small cell lung cancer (3,396) Hepatocellular carcinoma (1,255) Small cell lung cancer (1,063) Bile duct cancer (972) Non-small cell lung cancer stage iii (840) Small cell lung cancer extensive stage (660) Lung neoplasm malignant (641) Pancreatic carcinoma (584) Cholangiocarcinoma (444) Neoplasm malignant (253)

Other Drugs Used for K-ras gene mutation

SOTORASIB (752) AMG-510 (173) IRINOTECAN (40) PANITUMUMAB (36) CETUXIMAB (29) PEMBROLIZUMAB (28) BEVACIZUMAB (19) DALOTUZUMAB (18) CARBOPLATIN (17) FLUOROURACIL (17)

Related Pages

DURVALUMAB Full Profile All K-ras gene mutation Drugs DURVALUMAB Demographics DURVALUMAB Timeline